AIM (AIM ImmunoTech Inc.) Stock Analysis - Politician Trades

AIM ImmunoTech Inc. (AIM) is a publicly traded Healthcare sector company. As of May 21, 2026, AIM trades at $0.26 with a market cap of $6.36M and a P/E ratio of -0.05. AIM moved -38.69% today. Year to date, AIM is -80.10%; over the trailing twelve months it is +102.64%. Its 52-week range spans $0.06 to $20.33. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces AIM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded AIM stock?

Rallies tracks politician and congressional stock disclosures for AIM, including purchases, sales, transaction dates, owners, and reported trade amounts when available.

AIM Key Metrics

Key financial metrics for AIM
MetricValue
Price$0.26
Market Cap$6.36M
P/E Ratio-0.05
EPS$-8.62
Dividend Yield0.00%
52-Week High$20.33
52-Week Low$0.06
Volume11.72M
Avg Volume0
Revenue (TTM)$88.00K
Net Income$-13.96M
Gross Margin0.00%

Latest AIM News

Recent AIM Insider Trades

  • Equels Thomas K bought 107 (~$823.579) on Jun 13, 2025.
  • Equels Thomas K bought 103 (~$896.1) on Jun 12, 2025.
  • MITCHELL WILLIAM M bought 196.85K (~$5.00K) on Apr 11, 2025.

AIM Analyst Consensus

1 analysts cover AIM: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.

Common questions about AIM

Which politicians traded AIM stock?
Rallies tracks politician and congressional stock disclosures for AIM, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in AIM?
Yes. Rallies tracks politician and congressional stock disclosures for AIM, including reported purchases, sales, dates, owners, and trade amounts when available.
Is AIM research on Rallies investment advice?
No. Rallies provides research, data, and educational context for AIM. It does not provide personalized investment advice.
AIM

AIM